Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 16/2005

01-11-2005 | Adis Drug Profile

Docetaxel

In Hormone-Refractory Metastatic Prostate Cancer

Authors: Kate McKeage, Susan J. Keam

Published in: Drugs | Issue 16/2005

Login to get access

Abstract

▴ The taxoid analogue docetaxel is a potent inhibitor of microtubular depolymerisation and, in hormonerefractory metastatic prostate cancer, it also counters the effects of the anti-apoptotic protein Bcl-2.
▴ Overall survival was significantly increased in patients with hormone-refractory metastatic prostate cancer receiving intravenous docetaxel every 3 weeks plus oral prednisone or estramustine, compared with patients receiving intravenous mitoxantrone every 3 weeks plus prednisone in two large phase III trials (TAX 327 and SWOG [Southwest Oncology Group] 9916).
▴ In the TAX 327 study, patients receiving docetaxel 75 mg/m2 every 3 weeks plus prednisone had a median overall survival duration of 18.9 months; in the SWOG 9916 study, median overall survival duration was 17.5 months with docetaxel 60 mg/m2 every 3 weeks plus estramustine 280mg three times daily on days 1–5. The median overall survival duration for the control arm of mitoxantrone 12 mg/ m2 every 3 weeks plus prednisone was 16–17 months.
▴ Compared with mitoxantrone plus prednisone, docetaxel plus prednisone improved prostate specific antigen response rate, pain and health-related quality of life, and docetaxel plus estramustine increased progression-free survival.
▴ Adverse events were more common with docetaxel-than mitoxantrone-based treatment regimens, but mst events associated with docetaxel were mild-to-moderate in severity.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
2.
Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–20PubMedCrossRef
3.
de Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone-finally an effective chemotherapy. Eur J Cancer 2005 Mar; 41(4): 502–7PubMedCrossRef
4.
Dagher R, Li N, Abraham S, et al. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004 Dec 15; 10(24): 8147–51PubMedCrossRef
5.
Tannock IF, Osoba D, Stockier MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996; 14: 1756–64PubMed
6.
Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refactory prostate cancer: results of the Cancer and Leukemia Group B 9182 Study. J Clin Oncol 1999; 17: 2506–13PubMed
7.
Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 2004; 24: 2897–903PubMed
8.
Khan MA, Carducci MA, Partin AW. The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 2003 Nov; 170(5): 1709–16PubMedCrossRef
9.
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: the TAX 327 Investigators. N Engl J Med 2004; 351(15): 1502–12PubMedCrossRef
10.
Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13(10): 2643–55PubMed
11.
Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999; 26 (5 Suppl. 17): 3–7PubMed
12.
Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001; 28 (4 Suppl. 15): 3–7PubMedCrossRef
13.
Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst 1991; 83: 288–91PubMedCrossRef
14.
Díaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993; 32: 2747–55PubMedCrossRef
15.
Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996; 56(6): 1253–5PubMed
16.
McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52(24): 6940–4PubMed
17.
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–33PubMed
18.
Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 2001; 57(2): 366–70PubMedCrossRef
19.
Li Y, Hong X, Hussain M, et al. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther 2005; 4(3): 389–98PubMed
20.
Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate 2000; 44(4): 275–8PubMedCrossRef
21.
Fischel J-L, Ferrero J-M, Formento P, et al. Taxotere-5′-deox-y-5-fluorouridine combination on hormone-refractory human prostate cancer cells. Anti-Cancer Drugs 2005; 16(3): 309–16PubMedCrossRef
22.
Huang SF, Kim S-J, Lee AT, et al. Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-α-2b and docetaxel. Cancer Res 2002; 62(20): 5720–6PubMed
23.
Muramaki M, Miyake H, Hara I, et al. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. Int J Oncol 2005 Mar; 26(3): 623–8PubMed
24.
Hurtubise A, Momparler RL. Evaluation of antineoplastic action of 5-aza-2′-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines. Anti-Cancer Drugs 2004; 15(2): 161–7PubMedCrossRef
25.
Tolcher AW, Kuhn J, Schwartz G, et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the Bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004 Aug 1; 10(5): 5048–57PubMedCrossRef
26.
27.
Van Veldhuizen PJ, Reed G, Aggarwal A, et al. Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study. Cancer 2003; 98(9): 1855–62PubMedCrossRef
28.
Ikezoe T, Hisatake Y, Takeuchi T, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64(20): 7426–31PubMedCrossRef
29.
Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975; 1(3): 277–99PubMedCrossRef
30.
Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22(13): 2532–9PubMedCrossRef
31.
Oh WK, Halabi S, Kelly WK, et al. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. The Cancer and Leukemia Group B. Cancer 2003; 98(12): 2592–8
32.
Tolcher AW, Chi K, Kuhn J, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005; 11(10): 3854–61PubMedCrossRef
33.
Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21(1): 123–8PubMedCrossRef
34.
Goodin S, Rao KV, Kane M, et al. A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2005; 56(2): 199–204PubMedCrossRef
35.
European Medicines Agency. European Medicines Agency: Committee for Medicinal Products for Human Use, 13–16 September 2004 [media release; online]. Available from URL: http://​www.​emea.​eu.​int [Accessed 2005 Aug 28]
36.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology-v.2.2005: prostate cancer. 2005 Jul 26 [online]. Available from URL: http://​www.​nccn.​org [Accessed 2005 Aug 29]
Metadata
Title
Docetaxel
In Hormone-Refractory Metastatic Prostate Cancer
Authors
Kate McKeage
Susan J. Keam
Publication date
01-11-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 16/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565160-00003

Other articles of this Issue 16/2005

Drugs 16/2005 Go to the issue

Adis Drug Profile

Low-Dose Ethinylestradiol/Levonorgestrel

Adis Drug Evaluation

Oxycodone/Ibuprofen Combination Tablet

Current Opinion

Treatment for Erectile Dysfunction Based on Patient-Reported Outcomes

Adis Drug Profile

Docetaxel in Hormone-Refractory Metastatic Prostate Cancer

Adis Drug Evaluation

Escitalopram

Adis Drug Evaluation

Atazanavir